Tuberculosis is one of the infectious diseases that causes an important number of deaths in the world, along with AIDS and malaria. This situation is seen to get worse by the emergence of M. tuberculosis strains with major capacity of dissemination, multi-drug resistance (MDR), or extreme-drug resistance (XDR).  In Spain tuberculosis continues to be an important problem for the Public Health. Despite the fact that it showed a tendency of decrease between 1999 and 2004, but number of tuberculosis cases has been observed to increase since 2005. At present according to the estimation of the World Health Organization,the incidence in Spain has been reported to be 27 cases per 100 000 population. 

Our autonomous region of Aragon has an incidence close to the national average.


The team, created in 1992, has been a pioneer in the genetics of micobacteria in Spain and with an important international projection. Since its creation the team has been working in collaboration with other research groups, national and European and Latino American.

The interest of our group is reflected through the relevance of the research projects into which we participate. The group is currently participating in the FP7 Integrated Project “New TB VAC” (2010-2013) for the development of new vaccines to protect future generations against tuberculosis. Since 1998 the group has been coordinating and realizing the genetic study of multi-drug resistant M. tuberculosis in a systematic form; and it has impelled, in collaboration with the Health Institute Carlos III, the creation of a network of laboratories of the National System of Health for the study of multi-drug resistant tuberculosis in Spain. Since 2001, in collaboration with the Department of Health and Consumption of the Government of Aragon, the group has been involved in the characterization of the molecular assembly of M. tuberculosis isolated in Aragon.


All these activities have been possible to accomplish thanks to the continuous efforts of the group members, and to the continuous funding received at regional, national and European level since 1993. 

The group was recognized as a Consolidated Group of Research and Investigation by the Government of Aragon in 2003; and in 2006 the Health Institute Carlos III (Ministry of Health) recognized as a Biomedical Research Group (CIBER integral network of respiratory disease).